Skip to search formSkip to main contentSkip to account menu

Lumixyl

Known as: decapeptide-12 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Evaluation of a Novel Skin Brightening System Containing 0 . 01 % Decapeptide-12 for the Treatment of Mild to Moderate Facial
1Consultorio Sandra Ramírez, M.D.: calle 4 sur # 43 a 195 El Centro Ejecutivo oficina 253 C Medellín, Colombia 2Consultorio… 
2013
2013
Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma.
Melasma is a cutaneous disorder that primarily affects females of Hispanic and Asian descent. Previous studies have shown that… 
2012
2012
Treatment of mild to moderate facial melasma with the Lumixyl topical brightening system.
BACKGROUND Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary… 
2012
2012
Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12
This prospective study evaluated the safety and efficacy of decapeptide–12 in conjunction with an antioxidant cleanser, glycolic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)